JP2022552262A5 - - Google Patents
Info
- Publication number
- JP2022552262A5 JP2022552262A5 JP2022521243A JP2022521243A JP2022552262A5 JP 2022552262 A5 JP2022552262 A5 JP 2022552262A5 JP 2022521243 A JP2022521243 A JP 2022521243A JP 2022521243 A JP2022521243 A JP 2022521243A JP 2022552262 A5 JP2022552262 A5 JP 2022552262A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- approximately
- months
- mmol
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962911968P | 2019-10-07 | 2019-10-07 | |
| US62/911,968 | 2019-10-07 | ||
| PCT/US2020/054400 WO2021071835A1 (en) | 2019-10-07 | 2020-10-06 | Adeno-associated virus vector pharmaceutical composition and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022552262A JP2022552262A (ja) | 2022-12-15 |
| JP2022552262A5 true JP2022552262A5 (enExample) | 2023-10-17 |
Family
ID=73131798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022521243A Pending JP2022552262A (ja) | 2019-10-07 | 2020-10-06 | アデノ随伴ウイルスベクター医薬組成物および方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240108669A1 (enExample) |
| EP (1) | EP4041292A1 (enExample) |
| JP (1) | JP2022552262A (enExample) |
| KR (1) | KR20220081365A (enExample) |
| CN (4) | CN122005863A (enExample) |
| AR (1) | AR120171A1 (enExample) |
| AU (1) | AU2020362119A1 (enExample) |
| BR (1) | BR112022006718A2 (enExample) |
| CA (1) | CA3156984A1 (enExample) |
| IL (1) | IL291930A (enExample) |
| MX (1) | MX2022004146A (enExample) |
| TW (2) | TW202525312A (enExample) |
| WO (1) | WO2021071835A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3086045A1 (en) | 2017-12-19 | 2019-06-27 | Akouos, Inc. | Aav-mediated delivery of therapeutic antibodies to the inner ear |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| IL303737A (en) * | 2020-12-18 | 2023-08-01 | Sangamo Therapeutics Inc | Improved pharmaceutical compositions containing adeno-associated viral vector |
| CN119072302A (zh) * | 2022-03-14 | 2024-12-03 | 瑞泽恩制药公司 | Aav药物产品的冻干制剂 |
| TW202404651A (zh) * | 2022-04-06 | 2024-02-01 | 美商銳進科斯生物股份有限公司 | 用於脈絡膜上投與之調配物諸如形成聚集體之調配物 |
| EP4593955A1 (en) | 2022-09-30 | 2025-08-06 | RegenxBio Inc. | Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab |
| CN116350801A (zh) * | 2022-11-22 | 2023-06-30 | 四川至善唯新生物科技有限公司 | 一种重组腺相关病毒载体的药物组合物及其用途 |
| CN115869425B (zh) * | 2022-12-12 | 2024-08-20 | 北京生物制品研究所有限责任公司 | 一种aav眼用注射液及其制备方法和应用 |
| JP2026502876A (ja) * | 2022-12-23 | 2026-01-27 | スパーク セラピューティクス インコーポレイテッド | アデノ随伴ウイルス製剤 |
| WO2024220966A1 (en) * | 2023-04-21 | 2024-10-24 | The Regents Of The University Of California | Novel glycan compounds for age-related macular degeneration |
| WO2024238867A1 (en) | 2023-05-16 | 2024-11-21 | Regenxbio Inc. | Vectorized anti-complement antibodies and administration thereof |
| TW202508610A (zh) * | 2023-08-23 | 2025-03-01 | 大陸商上海瑞宏迪醫藥有限公司 | 醫藥組成物及其用途 |
| WO2025045082A1 (zh) * | 2023-09-01 | 2025-03-06 | 康霖生物科技（杭州）有限公司 | 一种缓冲系统及其相应液体制剂及其用途 |
| CN119769462A (zh) * | 2023-10-07 | 2025-04-08 | 陈国韬 | 一种非器质性（心理性）勃起功能障碍大鼠模型的构建方法 |
| WO2025113676A1 (en) * | 2023-11-29 | 2025-06-05 | Neuexcell Therapeutics (Suzhou) Co., Ltd. | Compositions and methods for treating stroke in primates |
| WO2025217230A1 (en) | 2024-04-08 | 2025-10-16 | Regenxbio Inc. | Vectorized anti-complement antibodies and complement agents and administration thereof |
| WO2026030714A1 (en) * | 2024-08-01 | 2026-02-05 | Sangamo Therapeutics, Inc. | Pharmaceutical compositions containing blood brain barrier penetrant aav capsids |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUT73101A (en) | 1993-02-12 | 1996-06-28 | Harvard College | Method for regulating transcription of targeted genes and other biological events |
| ATE544776T1 (de) | 1994-12-29 | 2012-02-15 | Massachusetts Inst Technology | Chimäre dna-bindeproteine |
| KR19990022651A (ko) | 1995-06-07 | 1999-03-25 | 데이비드 엘. 버스테인 | 생물학적 사건에 대한 라파마이신 기재 조절방법 |
| JP2003524368A (ja) | 1997-08-26 | 2003-08-19 | アリアド ジーン セラピューティクス インコーポレイテッド | ニ量化ドメイン、三量化ドメインまたは四量化ドメインおよび補足的非相同転写活性化ドメイン、転写抑制ドメイン、ｄｎａ結合ドメインまたはリガンド結合ドメインを含む融合蛋白 |
| IL134643A0 (en) | 1997-08-27 | 2001-04-30 | Ariad Gene Therapeutics Inc | Chimeric transcriptional activators and compositions and uses related thereto |
| WO1999036553A2 (en) | 1998-01-15 | 1999-07-22 | Ariad Gene Therapeutics, Inc. | Regulation of biological events using multimeric chimeric proteins |
| JP2002503667A (ja) | 1998-02-13 | 2002-02-05 | プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ | 新規な二量体化剤、その製造および使用 |
| US6689600B1 (en) * | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| US6596535B1 (en) | 1999-08-09 | 2003-07-22 | Targeted Genetics Corporation | Metabolically activated recombinant viral vectors and methods for the preparation and use |
| US7067526B1 (en) | 1999-08-24 | 2006-06-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
| CN103589692B (zh) | 2001-11-13 | 2018-07-24 | 宾夕法尼亚大学托管会 | 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法 |
| DK2359869T3 (en) | 2001-12-17 | 2019-04-15 | Univ Pennsylvania | Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof |
| EP1668143B1 (en) | 2003-09-30 | 2013-03-20 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
| ES2932278T3 (es) | 2004-06-01 | 2023-01-17 | Genzyme Corp | Composiciones y métodos para prevenir la agregación del vector AAV |
| DE23193606T1 (de) | 2005-04-07 | 2024-02-15 | The Trustees Of The University Of Pennsylvania | Verfahren zur erhöhung der funktion eines aav-vektors |
| JP4495210B2 (ja) | 2005-06-09 | 2010-06-30 | パナソニック株式会社 | 振幅誤差補償装置及び直交度誤差補償装置 |
| US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
| EA201190273A1 (ru) * | 2009-05-28 | 2012-12-28 | Глаксо Груп Лимитед | Комбинация антагониста tnf-альфа и антагониста vegf для применения в лечении или предупреждении заболеваний глаз |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| US8628966B2 (en) | 2010-04-30 | 2014-01-14 | City Of Hope | CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer |
| US10738326B2 (en) | 2010-10-27 | 2020-08-11 | Jichi Medical University | Adeno-associated virus vector for gene transfer to nervous system cells |
| CA2826273C (en) | 2011-02-10 | 2021-11-02 | The University Of North Carolina At Chapel Hill | Viral vectors with modified transduction profiles and methods of making and using the same |
| DK3693025T3 (da) | 2011-04-22 | 2022-01-10 | Univ California | Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf |
| EP3795581A3 (en) | 2011-08-24 | 2021-06-09 | The Board of Trustees of the Leland Stanford Junior University | New avv capsid proteins for nucleic acid transfer |
| US9827191B2 (en) * | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| EP3470523A1 (en) | 2012-05-09 | 2019-04-17 | Oregon Health & Science University | Adeno associated virus plasmids and vectors |
| EP2970946A4 (en) | 2013-03-13 | 2016-09-07 | Philadelphia Children Hospital | ADENOASSOZED VIRUS VECTORS AND METHOD FOR USE THEREOF |
| EP3564379A1 (en) | 2013-09-13 | 2019-11-06 | California Institute of Technology | Selective recovery |
| HUE052676T2 (hu) | 2013-10-11 | 2021-05-28 | Massachusetts Eye & Ear Infirmary | Eljárások õsi vírusszekvenciák elõrejelzésére és alkalmazásaik |
| WO2015138604A1 (en) * | 2014-03-12 | 2015-09-17 | University Of Virginia Patent Foundation | Compositions and methods for treating eye infections and disease |
| US10746742B2 (en) | 2014-04-25 | 2020-08-18 | Oregon Health & Science University | Methods of viral neutralizing antibody epitope mapping |
| US10064752B2 (en) | 2014-09-11 | 2018-09-04 | Orbit Biomedical Limited | Motorized suprachoroidal injection of therapeutic agent |
| JP2019515027A (ja) | 2016-04-15 | 2019-06-06 | レジェンクスバイオ インコーポレーテッド | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
| IL262207B2 (en) * | 2016-04-15 | 2026-01-01 | Univ Pennsylvania | Preparations for the treatment of wet age-related macular degeneration |
| PL3472317T3 (pl) * | 2016-06-16 | 2022-08-08 | Adverum Biotechnologies, Inc. | Kompozycje i sposoby zmniejszania neowaskularyzacji oka |
| CN110300591A (zh) * | 2016-11-04 | 2019-10-01 | 百深公司 | 腺相关病毒制剂 |
| US11512327B2 (en) * | 2017-08-03 | 2022-11-29 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of AAV |
| CA3076905A1 (en) | 2017-09-27 | 2019-04-04 | The Johns Hopkins University | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
| KR20260086827A (ko) * | 2018-11-14 | 2026-06-10 | 리젠엑스바이오 인크. | 신경원성 세로이드 리포푸신증에 대한 유전자 요법 |
-
2020
- 2020-10-06 WO PCT/US2020/054400 patent/WO2021071835A1/en not_active Ceased
- 2020-10-06 CN CN202610160081.4A patent/CN122005863A/zh active Pending
- 2020-10-06 CN CN202610171188.9A patent/CN122005864A/zh active Pending
- 2020-10-06 US US17/766,941 patent/US20240108669A1/en active Pending
- 2020-10-06 JP JP2022521243A patent/JP2022552262A/ja active Pending
- 2020-10-06 EP EP20801425.8A patent/EP4041292A1/en active Pending
- 2020-10-06 CN CN202610160082.9A patent/CN122342838A/zh active Pending
- 2020-10-06 MX MX2022004146A patent/MX2022004146A/es unknown
- 2020-10-06 IL IL291930A patent/IL291930A/en unknown
- 2020-10-06 KR KR1020227015158A patent/KR20220081365A/ko active Pending
- 2020-10-06 CN CN202080079668.3A patent/CN114728049A/zh active Pending
- 2020-10-06 BR BR112022006718A patent/BR112022006718A2/pt unknown
- 2020-10-06 CA CA3156984A patent/CA3156984A1/en active Pending
- 2020-10-06 AU AU2020362119A patent/AU2020362119A1/en active Pending
- 2020-10-07 TW TW114110012A patent/TW202525312A/zh unknown
- 2020-10-07 AR ARP200102778A patent/AR120171A1/es unknown
- 2020-10-07 TW TW109134835A patent/TWI879814B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7740842B2 (en) | Stable liquid formulations of antibodies | |
| JP2024178197A (ja) | 液体医薬組成物 | |
| AU2013255413C1 (en) | Pharmaceutical formulations of TNF-alpha antibodies | |
| CN102946861B (zh) | 浓缩蛋白制剂及其用途 | |
| CN1293916C (zh) | 稳定的胰岛素制剂 | |
| JP2022153418A5 (enExample) | ||
| JP2024016207A5 (enExample) | ||
| JP7089121B2 (ja) | 高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤 | |
| JP2021504372A5 (enExample) | ||
| JP2021516671A5 (enExample) | ||
| AU2016280555A1 (en) | Anti-CGRP antibody formulation | |
| JP2022545967A5 (enExample) | ||
| WO2023011502A1 (zh) | 含有抗il-4r抗体的稳定制剂 | |
| WO2019020777A1 (en) | LIQUID FORMULATION OF A VEGF ANTAGONIST | |
| CN104936607A (zh) | 稳定的TNFR:Fc融合蛋白药物组合物 | |
| CN116056688A (zh) | 眼用液体组合物 | |
| CN107205925A (zh) | 液体药物组合物 | |
| CN118056572A (zh) | 含有抗il-17抗体的稳定制剂 | |
| JP6852049B2 (ja) | 改善された安定性を有するエタネルセプト組成物 | |
| WO2025177156A1 (en) | Stable ophthalmic pharmaceutical formulation of aflibercept | |
| AU2006202688B2 (en) | Stable liquid formulations of antibodies | |
| AU2002321055A1 (en) | Stable liquid formulations of antibodies | |
| OA17126A (en) | Pharmaceutical formulations of TNF-alpha antibodies | |
| HK1207316B (en) | Anti-prolactin receptor antibody formulations |